Mersana Therapeutics Announces Completion of Enrollment in UPLIFT, a Single-Arm Registrational Trial of Upifitamab Rilsodotin (UpRi) in Platinum-Resistant Ovarian Cancer
Topline data from UPLIFT expected in mid-2023 Targeting potential Biologics License Application (BLA) submission by…